HCV Yields to Combo, While HIV Stays Suppressed

WASHINGTON — Combination therapy to treat patients co-infected with HIV and hepatitis C virus (HCV) can achieve a high percentage of virologic end-of-treatment response to the hepatitis infection without affecting suppression of the HIV, researchers reported here.

At 48 weeks, 83% of patients had a sustained response to hepatitis infection with the combination of telaprevir (Incivek)-pegylated interferon and ribavirin, and maintained suppression of HIV to less than 50 copies/mL, said Laurent Cotte, MD, co-ordinator of the study for the French National Agency for Research (ANRS), and a physician at Centre Hospitalier Universitaire de Lyon.

More than half the patients with HIV in France are co-infected with hepatitis C virus making this population of patients difficult to treat, Cotte told MedPage Today at the annual meeting of the American Association for the Study of Liver Diseases.

“Despite a high discontinuation rate related to toxicity (20.3%), a very high virological response rate was achieved at Week 48 with the combination therapy in patients who were already experienced with pegylated-ribavirin HIV co-infected patients,” Cotte said at his poster presentation.

Ed Susman , Contributing Writer
MedPage Today
Read More

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below

Laboratory Order Forms

Start typing and press enter to search